mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

MEDIA

We are open for communication and dialogue.

Our Company is one of the first on the Russian venture investment market. For more than 8 years, Maxwell Biotech has been working in the field of biotechnology and pharmaceuticals and has a unique team capable of implementing highly advanced and complicated projects. During these years we have accumulated great experience in managing venture projects, developing medical drugs, conducting clinical trials and in successful international partnership.

Our experts are prepared to share their vision of venture investment prospects, to speak about the medications we develop, relevant trends, assessing the current progress in the industry and sharing our successful experience in addressing specific issues in real-life cases.

In the attached files you can find the profile of Maxwell Biotech Group’s speaker, detailed information about portfolio companies and medical drugs under development.

Maxwell Biotech Group, +7 (495) 726-52-53, bakrenko@ammaxwell.ru

© Maxwell Biotech Group Ltd.

TOP